Exicure

XCUR

Market cap $32.5M

Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today shared recent progress for its lead program, burixafor (GPC-100), outlined upcoming strategic priorities, and introduced new members of its leadership team who will help drive the company's next phase of growth.

Exicure Posts Wider Loss in Fiscal Q2

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).